SCHEMBL487462

SCHEMBL487462

CC(C)(C)OC(=O)C(O)COCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.54
CTSS P25774 1/20 0.51
CA1 P00915 3/20 0.50
PPARG P37231 1/20 0.49
L3MBTL1 Q9Y468 3/20 0.48
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
NPSR1 Q6W5P4 1/20 0.46
SYK P43405 1/20 0.45
KLK7 P49862 1/20 0.45
KLK5 Q9Y337 1/20 0.45
ALDH1A1 P00352 1/20 0.45
SLC1A1 P43005 1/20 0.44
CASR P41180 1/20 0.43
LTA4H P09960 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL487460 1.00 PPARA (0.54) PPARACTSSCA1PPARGL3MBTL1
SCHEMBL23541264 1.00 PPARA (0.54) PPARACTSSCA1PPARGL3MBTL1
SCHEMBL486967 0.85 L3MBTL1 (0.49) PPARACTSSCA1PPARGL3MBTL1
SCHEMBL30598766 0.85 L3MBTL1 (0.49) PPARACTSSCA1PPARGL3MBTL1
SCHEMBL486968 0.85 L3MBTL1 (0.49) PPARACTSSCA1PPARGL3MBTL1
SCHEMBL3732892 0.85 PPARA (0.57) PPARACTSSCA1PPARGL3MBTL1
SCHEMBL7279136 0.84 PPARA (0.53) PPARACTSSCA1PPARGL3MBTL1
SCHEMBL7338978 0.84 SLC1A1 (0.54) PPARACTSSCA1PPARGL3MBTL1
SCHEMBL2584804 0.84 SLC1A1 (0.54) PPARACTSSCA1PPARGL3MBTL1
SCHEMBL9025179 0.84 PPARA (0.53) PPARACTSSCA1PPARGL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof ABBVIE INC. 2024-11-21 US disclosed
CN-116194453-A Protein tyrosine phosphatase degrading agent and method of use thereof 卡里科生命科学有限责任公司 2023-05-30 CN disclosed
EP-4077319-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2022-10-26 EP disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 WO disclosed
US-8362043-B2 Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, 3(R,S)-[2(S)-(3-Benzoylamino-2-oxo-2H-pyridin-1-yl)-3-phenyl-propionylamino]-5-fluoro-4-oxo-pentanoic acid VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-29 US disclosed
EP-1833794-B1 3-[2-(3-ACYLAMINO-2-OXO-2H-PYRIDIN-1-YL)-ACETYLAMINO]-4-OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS VERTEX PHARMA (US) 2012-02-01 EP disclosed
US-20060160862-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof PTPN5, PTPN1, PTPN2 PPARA 3458/4885CTSS 2265/4885CA1 4518/4885
US-20060160862-A1 Caspase inhibitors and uses thereof CASP1, CASP5, CASP3 PPARA 3976/4885CTSS 68/4885CA1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.